Insilico Medicine announces ARDD 2026 program, bringing global leaders in longevity biotechnology to Boston
Meeting Announcement
Updates every hour. Last Updated: 21-Oct-2026 06:16 ET (21-Oct-2026 10:16 GMT/UTC)
Insilico Medicine has announced the program for ARDD 2026, the 13th Aging Research & Drug Discovery Meeting, taking place October 1–3 at the David Rubenstein Treehouse at Harvard University in Boston.
The three-day program will convene global leaders from pharmaceutical and biotechnology companies, academia, clinical medicine, investment, artificial intelligence, scientific publishing and policy. Sessions will span aging biology, therapeutic discovery, clinical development, regulatory strategy, partnering and investment, reflecting the growing maturity of longevity biotechnology.
Insilico Medicine has announced the program for ARDD 2026, the 13th Aging Research & Drug Discovery Meeting, taking place October 1–3 at the David Rubenstein Treehouse at Harvard University in Boston.
The three-day program will convene global leaders from pharmaceutical and biotechnology companies, academia, clinical medicine, investment, artificial intelligence, scientific publishing and policy. Sessions will span aging biology, therapeutic discovery, clinical development, regulatory strategy, partnering and investment, reflecting the growing maturity of longevity biotechnology.
Two-thirds of Americans favor banning the use of the herbicide glyphosate, the active ingredient in the popular weed killer Roundup, on crops grown in the United States, according to a nationally representative survey conducted by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania.
Large language models (LLMs), including the models behind ChatGPT and Claude as well as numerous other systems developed specifically for medical applications, are increasingly used in clinical workflows. They support medical documentation, summarize knowledge, and assist with clinical decision-making. However, their adoption is outpacing the development of systems for oversight and safety. An interdisciplinary team of researchers at the Else Kröner Fresenius Center (EKFZ) for Digital Health at TUD Dresden University of Technology and University Hospital Dresden, together with national and international colleagues, has systematically analyzed the risks associated with LLM use in medicine. The review, published in Nature, brings together evidence from medical AI, cybersecurity, regulatory science, ethics and behavioral psychology and outlines strategies for trustworthy and responsible use of artificial intelligence (AI) in clinical practice.
As climate impacts are intensifying worldwide, there is an urgent demand for information on how to respond. IIASA researchers and partners have developed a new tool that meets that need, integrating climate drivers, risks, and adaptation options in one framework grounded in IPCC science. It turns authoritative global climate assessments into guidance practitioners can use.